HC Wainwright reiterated their buy rating on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) in a research note issued to investors on Wednesday, TipRanks reports. They currently have a $9.50 target price on the stock.
A number of other research firms also recently commented on ARMP. LADENBURG THALM/SH SH reaffirmed a buy rating and set a $9.00 price objective on shares of Armata Pharmaceuticals in a research note on Wednesday, August 21st. Zacks Investment Research raised shares of Armata Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, October 21st.
ARMP stock traded up $0.16 during trading on Wednesday, hitting $4.17. The stock had a trading volume of 7,927 shares, compared to its average volume of 47,562. Armata Pharmaceuticals has a 1-year low of $2.10 and a 1-year high of $6.23.
An institutional investor recently bought a new position in Armata Pharmaceuticals stock. Vanguard Group Inc. bought a new position in shares of Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,151 shares of the company’s stock, valued at approximately $61,000. Vanguard Group Inc. owned approximately 0.63% of Armata Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.
Read More: Fibonacci Channel
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.